{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:57:53Z","timestamp":1790546273284,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030734","name":"J-Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37414","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:16:11Z","timestamp":1725394571000},"page":"e37414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance of LAT1 expression in pleural mesothelioma"],"prefix":"10.1016","volume":"10","author":[{"given":"Ryo","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Umesaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nitanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirozo","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e37414_bib1","doi-asserted-by":"crossref","first-page":"23629","DOI":"10.1074\/jbc.273.37.23629","article-title":"Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)","volume":"273","author":"Kanai","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e37414_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0005-2736(01)00384-4","article-title":"Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines","volume":"1514","author":"Yanagida","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.heliyon.2024.e37414_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semcancer.2005.04.005","article-title":"Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?","volume":"15","author":"Fuchs","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.heliyon.2024.e37414_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.bjc.6604235","article-title":"Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer","volume":"98","author":"Kaira","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e37414_bib5","article-title":"Prognostic value of LAT-1 status in solid cancer: a systematic review and meta-analysis","volume":"15","author":"Lu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e37414_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicenter, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e37414_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e37414_bib8","first-page":"4075","article-title":"L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma","volume":"31","author":"Kaira","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2024.e37414_bib9","article-title":"Amino-acid transporters in T-cell activation and differentiation","volume":"8","author":"Ren","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.heliyon.2024.e37414_bib10","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.3390\/ijms24043618","article-title":"Systemic inflammation\/nutritional status scores are prognostic but not predictive in metastatic non-small-cell lung cancer treated with first-line immune checkpoint inhibitors","volume":"24","author":"Mahiat","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e37414_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2021.06.024","article-title":"Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET\/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy","volume":"159","author":"Seban","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.heliyon.2024.e37414_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2407-13-158","article-title":"Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review","volume":"13","author":"Jafri","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e37414_bib13","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1002\/cam4.4220","article-title":"Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer","volume":"10","author":"Imai","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2024.e37414_bib14","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/bjc.2014.88","article-title":"ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer","volume":"110","author":"Shimizu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e37414_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37414_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1440-1827.2008.02319.x","article-title":"L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer","volume":"59","author":"Sakata","year":"2009","journal-title":"Pathol. Int."},{"key":"10.1016\/j.heliyon.2024.e37414_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3892\/or.2022.8429","article-title":"Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC","volume":"48","author":"Kaira","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e37414_bib18","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1111\/1759-7714.15082","article-title":"Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib","volume":"14","author":"Kaira","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.heliyon.2024.e37414_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12672-023-00615-4","article-title":"Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer","volume":"14","author":"Kaira","year":"2023","journal-title":"Discov Oncol"},{"key":"10.1016\/j.heliyon.2024.e37414_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","author":"Okano","year":"2020","journal-title":"Invest. N. Drugs"},{"issue":"suppl 4","key":"10.1016\/j.heliyon.2024.e37414_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2023.41.4_suppl.494","article-title":"Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients pretreated advanced refractory biliary tract cancer (BTC): primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study","volume":"41","author":"Furse","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37414_bib22","first-page":"468","article-title":"LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer","volume":"3","author":"Kaira","year":"2011","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.heliyon.2024.e37414_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e37414_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4049\/jimmunol.1701477","article-title":"mTORC1 signaling regulates the generation and function of central and effector FoxP3+ regulatory T cells","volume":"201","author":"Sun","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e37414_bib25","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/s41598-022-06615-8","article-title":"Assocaition of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer","volume":"12","author":"Kurozumi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e37414_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103031","article-title":"LAT1 enables T cell activation under inflammatory conditions","volume":"138","author":"Ogbechi","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.heliyon.2024.e37414_bib27","article-title":"Phase II placebo-controlled study of the effect and safety of nanvuranlat in patients with advanced biliary tract cancers previously treated by systemic chemotherapy","volume":"26","author":"Furuse","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024134457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024134457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:24:27Z","timestamp":1790544267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024134457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024134457"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37414","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of LAT1 expression in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37414"}}